Emerging drugs for psoriasis

Bibliography

• CHRISTOPHERS E: Psoriasis – epidemiology and clinical spectrum. Clin. Exp. Dermatol. (2001) 26:314-320.
   PubMed Web of Science ®Google Scholar
• GIARDINA E, SINIBALDI C, NOVELLI G: The psoriasis genetics as a model of complex disease. Curr. Drug. Targets Inflamm. Allergy (2004) 3:129-136.
   PubMedGoogle Scholar
• HENSELER T, CHRISTOPHERS E: Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J. Am. Acad. Dermatol. (1985) 13:450-456.
   PubMed Web of Science ®Google Scholar
• INTERNATIONAL PSORIASIS GENETICS CONSORTIUM: The International Psoriasis Genetics Study: assessing linkage to 14 candidate susceptibility loci in a cohort of 942 affected sib pairs. Am. J. Hum. Genet. (2003) 73:430-437.
   PubMed Web of Science ®Google Scholar
• SAGOO GS, CORK MJ, PATEL R, TAZI-AHNINI R: Genome-wide studies of psoriasis susceptibility loci: a review. J. Dermatol. Sci. (2004) 35:171-179.
   PubMed Web of Science ®Google Scholar
• KRUEGER JG: The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. (2002) 46:1-23.
   PubMed Web of Science ®Google Scholar
• GLADMAN DD, ANTONI C, MEASE P, CLEGG DO, NASH P: Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis. (2005) 64(Suppl. 2):14-17.
   Web of Science ®Google Scholar
• CHAMIAN F, KRUEGER JG: Psoriasis vulgaris: an interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in pathogenesis. Curr. Opin. Rheumatol. (2004) 16:331-337.
   PubMed Web of Science ®Google Scholar
• BOS JD, DE RIE MA, TEUNISSEN MB, PISKIN G: Psoriasis: dysregulation of innate immunity. Br. J. Dermatol. (2005) 152:1098-1107.
   PubMed Web of Science ®Google Scholar
• GASPARI AA: Innate and adaptive immunity and the pathophysiology of psoriasis. J. Am. Acad. Dermatol. (2006) 54(3 Suppl. 2):S67-S80.
   PubMed Web of Science ®Google Scholar
• KRUEGER GG, FELDMAN SR, CAMISA C et al.: Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J. Am. Acad. Dermatol. (2000) 43:281-285.
   PubMed Web of Science ®Google Scholar
• RICHARDS HL, FORTUNE DG, GRIFFITHS CE, MAINE CJ: The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J. Psychosom. Res. (2001) 50:11-15.
   PubMed Web of Science ®Google Scholar
• GELFAND JM, FELDMAN SR, STERN RS, THOMAS J, ROLSTAD T, MARGOLIS DJ: Determinants of quality of life in patients with psoriasis: a study from the US population. J. Am. Acad. Dermatol. (2004) 51:704-708.
   PubMed Web of Science ®Google Scholar
• STERN RS, NIJSTEN T, FELDMAN SR, MARGOLIS DJ, ROLSTAD T: Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J. Investig. Dermatol. Symp. Proc. (2004) 9:136-139.
   PubMed Web of Science ®Google Scholar
• SAMPOGNA F, TABOLLI S, SODERFELDT B, AXTELIUS B, APARO U, ABENI D: Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br. J. Dermatol. (2006) 154:844-849.
   PubMed Web of Science ®Google Scholar
• HEYDENDAEL VM, DE BORGIE CA, SPULS PI, BOSSUYT PM, BOS JD, DE RIE MA: The burden of psoriasis is not determined by disease severity only. J. Investig. Dermatol. Symp. Proc. (2004) 9:131-135.
   PubMed Web of Science ®Google Scholar
• HENSELER T, CHRISTOPHERS E: Disease concomitance in psoriasis. J. Am. Acad. Dermatol. (1995) 32:982-986.
   PubMed Web of Science ®Google Scholar
• PEARCE DJ, MORRISON AE, HIGGINS KB et al.: The comorbid state of psoriasis patients in a university dermatology practice. J. Dermatolog. Treat. (2005) 16:319-323.
   PubMed Web of Science ®Google Scholar
• MALLBRIS L, GRANATH F, HAMSTEN A, STAHLE M: Psoriasis is associated with lipid abnormalities at the onset of skin disease. J. Am. Acad. Dermatol. (2006) 54:614-621.
   PubMed Web of Science ®Google Scholar
• CROWN WH, BRESNAHAN BW, ORSINI LS, KENNEDY S, LEONARDI C: The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr. Med. Res. Opin. (2004) 20:1929-1936.
   PubMed Web of Science ®Google Scholar
• STERN RS: Utilization of outpatient care for psoriasis. J. Am. Acad. Dermatol. (1996) 35:543-545.
   PubMed Web of Science ®Google Scholar
• JAVITZ HS, WARD MM, FARBER E, NAIL L, VALLOW SG: The direct cost of care for psoriasis and psoriatic arthritis in the United States. J. Am. Acad. Dermatol. (2002) 46:850-860.
   PubMed Web of Science ®Google Scholar
• SOHN S, SCHOEFFSKI O, PRINZ J et al.: Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology (2006) 212:137-144.
   PubMed Web of Science ®Google Scholar
• KIMBALL AB, JACOBSON C, WEISS S, VREELAND MG, WU Y: The psychosocial burden of psoriasis. Am. J. Clin. Dermatol. (2005) 6:383-392.
   PubMed Web of Science ®Google Scholar
• PEARCE DJ, SINGH S, BALKRISHNAN R, KULKARNI A, FLEISCHER AB, FELDMAN SR: The negative impact of psoriasis on the workplace. J. Dermatolog. Treat. (2006) 17:24-28.
   PubMed Web of Science ®Google Scholar
• PEARCE DJ, NELSON AA, FLEISCHER AB, BALKRISHNAN R, FELDMAN SR: The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J. Dermatolog. Treat. (2006) 17:29-37.
   PubMed Web of Science ®Google Scholar
• JAVITZ HS, WARD MM, FARBER E, NAIL L, VALLOW SG: The direct cost of care for psoriasis and psoriatic arthritis in the United States. J. Am. Acad. Dermatol. (2002) 46:850-860.
   PubMed Web of Science ®Google Scholar
• STEIN KR, PEARCE DJ, FELDMAN SR: The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin. Cutan. Med. Surg. (2005) 24:52-57.
   PubMed Web of Science ®Google Scholar
• NIJSTEN T, ROLSTAD T, FELDMAN SR, STERN RS: Members of the National Psoriasis Foundation: more extensive disease and better informed about treatment options. Arch. Dermatol. (2005) 141:19-26.
   PubMed Web of Science ®Google Scholar
• STERN RS, NIJSTEN T, FELDMAN SR, MARGOLIS DJ, ROLSTAD T: Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J. Investig. Dermatol. Symp. Proc. (2004) 9:136-139.
   PubMed Web of Science ®Google Scholar
• KRUEGER G, KOO J, LEBWOHL M, MENTER A, STERN RS, ROLSTAD T: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. (2001) 137:280-284.
   PubMed Web of Science ®Google Scholar
• RICHARDS HL, FORTUNE DG, GRIFFITHS CE: Adherence to treatment in patients with psoriasis. J. Eur. Acad. Dermatol. Venereol. (2006) 20:370-379.
   PubMed Web of Science ®Google Scholar
• NIJSTEN T, MARGOLIS DJ, FELDMAN SR, ROLSTAD T, STERN RS: Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J. Am. Acad. Dermatol. (2005) 52:434-444.
   PubMed Web of Science ®Google Scholar
• AL-SUWAIDAN SN, FELDMAN SR: Clearance is not a realistic expectation of psoriasis treatment. J. Am. Acad. Dermatol. (2000) 42:796-802.
   PubMed Web of Science ®Google Scholar
• FORTUNE DG, RICHARDS HL, KIRBY B, MCELHONE K, MAIN CJ, GRIFFITHS CE: Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patients’ well-being. Br. J. Dermatol. (2004) 151:1219-1226.
   PubMed Web of Science ®Google Scholar
• FELDMAN SR, NIJSTEN T, MARGOLIS DJ, ROLSTAD T: Systemic therapy does not usually clear psoriasis, but treatment success does not require clearing. J. Am. Acad. Dermatol. (2005) 52:140-141.
   PubMed Web of Science ®Google Scholar
• HOUSMAN TS, MELLEN BG, RAPP SR, FLEISCHER AB JR, FELDMAN SR: Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis (2002) 70:327-332.
   PubMed Web of Science ®Google Scholar
• CALLEN JP, KRUEGER GG, LEBWOHL M et al.: AAD consensus statement on psoriasis therapies. J. Am. Acad. Dermatol. (2003) 49:897-899.
   PubMed Web of Science ®Google Scholar
• VAN DE KERKHOF PC, VISSERS WH: Established treatments of psoriasis. Curr. Drug. Targets Inflamm. Allergy (2004) 3:145-156.
   PubMedGoogle Scholar
• AFIFI T, DE GANNES G, HUANG C, ZHOU Y: Topical therapies for psoriasis: evidence-based review. Can. Fam. Physician. (2005) 51:519-525.
   PubMed Web of Science ®Google Scholar
• VAN DE KERKHOF PCM, KRAGBALLE K: Recommendations for the topical treatment of psoriasis. J. Eur. Acad. Dermatol. Venereol. (2005) 19:495-499.
   PubMed Web of Science ®Google Scholar
• NALDI L, GRIFFITHS CE: Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br. J. Dermatol. (2005) 152:597-615.
   PubMed Web of Science ®Google Scholar
• FREDRIKSEN T, PETTERSON U: Severe psoriasis – oral therapy with a new retinoid. Dermatologica (1978) 157:238-244.
   PubMedGoogle Scholar
• KRAGBALLE K, AUSTAD J, BARNES L et al.: A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br. J. Dermatol. (2006) 154:1155-1160.
   PubMed Web of Science ®Google Scholar
• LEBWOHL M, FREEMAN AK, CHAPMAN MS, FELDMAN SR, HARTLE JE, HENNING A: Tacrolimus ointment is effective for facial and intertriginous psoriasis. J. Am. Acad. Dermatol. (2004) 51:723-730.
   PubMed Web of Science ®Google Scholar
• GRIBETZ C, LING M, LEBWOHL M et al.: Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J. Am. Acad. Dermatol. (2004) 51:731-738.
   PubMed Web of Science ®Google Scholar
• KOLLNER K, WIMMERSHOFF MB, HINTZ C, LANDTHALER M, HOHENLEUTNER U: Comparison of the 308-nm excimer laser and a 308-nm excimer lamp with 311-nm narrowband ultraviolet B in the treatment of psoriasis. Br. J. Dermatol. (2005) 152:750-754.
   PubMed Web of Science ®Google Scholar
• FRASER AD, VAN KUIJK AW, WESTHOVENS R et al.: A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann. Rheum. Dis. (2005) 64:859-864.
   PubMed Web of Science ®Google Scholar
• THOMAS JA, AITHAL GP: Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary? Am. J. Clin. Dermatol. (2005) 6:357-363.
   PubMed Web of Science ®Google Scholar
• HO VC, GRIFFITHS CE, ALBRECHT G et al.: Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Br. J. Dermatol. (1999) 141:283-291.
   PubMed Web of Science ®Google Scholar
• GRIFFITHS CE, DUBERTRET L, ELLIS CN et al.: Ciclosporin in psoriasis clinical practice: an international consensus statement. Br. J. Dermatol. (2004) 150(Suppl. 67):11-23.
   PubMed Web of Science ®Google Scholar
• TREUMER F, ZHU K, GLASER R, MROWIETZ U: Dimethylfumarate is a potent inducer of apoptosis in human T cells. J. Invest. Dermatol. (2003) 121:1383-1388.
   PubMed Web of Science ®Google Scholar
• LITJENS NHR, RADEMAKER M, RAVENSBERGEN B et al.: Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated TH1 lymphocyte responses. Eur. J. Immunol. (2004) 34:565-575.
   PubMed Web of Science ®Google Scholar
• STROBER BE, SIU K, MENON K: Conventional systemic agents for psoriasis. A systematic review. J. Rheumatol. (2006) 33:1442-1446.
   PubMed Web of Science ®Google Scholar
• KOO J, KHERA P: Update on the mechanisms and efficacy of biological therapies for psoriasis. J. Dermatol. Sci. (2005) 38:75-87.
   PubMed Web of Science ®Google Scholar
• PAPP KA: The long-term efficacy and safety of new biological therapies for psoriasis. Arch. Dermatol. Res. (2006) 298:7-15.
   PubMed Web of Science ®Google Scholar
• VAN DE KERKHOF PC: Consistent control of psoriasis by continuous long-term therapy: the promise of biological treatments. J. Eur. Acad. Dermatol. Venereol. (2006) 20:639-650.
   PubMed Web of Science ®Google Scholar
• LEW W, BOWCOCK AM, KRUEGER JG: Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and ‘type 1’ inflammatory gene expression. Trends Immunol. (2004) 25:295-305.
   PubMed Web of Science ®Google Scholar
• NICKOLOFF BJ, WRONE-SMITH T: Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am. J. Pathol. (1999) 155:145-158.
   PubMed Web of Science ®Google Scholar
• HIDA S, OGASAWARA K, SATO K et al.: CD8 (+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity (2000) 13:643-655.
   PubMed Web of Science ®Google Scholar
• KOHLMANN WM, URBAN W, STERRY W, FOERSTER J: Correlation of psoriasis activity with abundance of CD25+CD8+ T cells: conditions for cloning T cells from psoriatic plaques. Exp. Dermatol. (2004) 13:607-612.
   PubMed Web of Science ®Google Scholar
• CLARK RA, KUPPER TS: Misbehaving macrophages in the pathogenesis of psoriasis. J. Clin. Invest. (2006) 116:2084-2087.
   PubMed Web of Science ®Google Scholar
• NESTLE FO, CONRAD C, TUN-KYI A et al.: Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J. Exp. Med. (2005) 202:135-143.
   PubMed Web of Science ®Google Scholar
• IBANEZ A, SARRIAS MR, FARNOS M et al.: Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor. J. Immunol. (2006) 177:1152-1159.
   PubMed Web of Science ®Google Scholar
• RUDENSKY A, BEERS C: Lysosomal cysteine proteases and antigen presentation. Ernst Schering Res. Found. Workshop (2006) 56:81-95.
   PubMedGoogle Scholar
• SCHWARZ G, BOEHNCKE WH, BRAUN M et al.: Cathepsin S activity is detectable in human keratinocytes and is selectively upregulated upon stimulation with interferon-gamma. J. Invest. Dermatol. (2002) 119:44-49
   PubMed Web of Science ®Google Scholar
• PAPAGEORGIOU AC, WIKMAN LE: Is JAK3 a new drug target for immunomodulation-based therapies? Trends Pharmacol. Sci. (2004) 25:558-562.
   PubMed Web of Science ®Google Scholar
• CHATILA TA: Role of regulatory T cells in human diseases. J. Allergy Clin. Immunol. (2005) 116:949-959.
   PubMed Web of Science ®Google Scholar
• VELDMAN C, NAGEL A, HERTL M: Type I regulatory T cells in autoimmunity and inflammatory diseases. Int. Arch. Allergy Immunol. (2006) 140:174-183.
   PubMed Web of Science ®Google Scholar
• SUGIYAMA H, GYULAI R, TOICHI E et al.: Dysfunctional blood and target tissue CD4+CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J. Immunol. (2005) 174:164-173.
   PubMed Web of Science ®Google Scholar
• SUCIU-FOCA N, MANAVALAN JS, CORTESINI R: Generation and function of antigen-specific suppressor and regulatory T cells. Transpl. Immunol. (2003) 11:235-244.
   PubMed Web of Science ®Google Scholar
• WHARTENBY KA, CALABRESI PA, MCCADDEN E et al.: Inhibition of FLT3 signaling targets DC sto ameliorate autoimmune disease. Proc. Natl. Acad. Sci. USA (2005) 102:16741-16746.
   PubMed Web of Science ®Google Scholar
• GNIADECKI R, CALVERLEY MJ: Emerging drugs in psoriasis. Expert. Opin. Emerg. Drugs (2002) 7:69-90.
   PubMedGoogle Scholar
• CATHER JC, CATHER JC, ABRAMOVITS W: Investigational therapies for psoriasis. J. Am. Acad. Dermatol. (2003) 49(2 Suppl.):S133-S138.
   PubMed Web of Science ®Google Scholar
• SCHLEYER V, LANDTHALER M, SZEIMIES RM: Novel pharmacological approaches in the treatment of psoriasis. J. Eur. Acad. Dermatol. Venereol. (2005) 19:1-20.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB AB, LEBWOHL M, SHIRIN S et al.: Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J. Am. Acad. Dermatol. (2000) 43:595-604.
   PubMed Web of Science ®Google Scholar
• SKOV L, KRAGBALLE K, ZACHARIAE C et al.: HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch. Dermatol. (2003) 139:1433-1439.
   PubMed Web of Science ®Google Scholar
• CHATENOUD L: CD3-specific antibodies as promising tools to aim at immune tolerance in the clinic. Int. Rev. Immunol. (2006) 25:215-233.
   PubMed Web of Science ®Google Scholar
• GORDON KB, VAISHNAW AK, O’GORMAN J, HANEY J, MENTER A: Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch. Dermatol. (2003) 139:1563-1570.
   PubMed Web of Science ®Google Scholar
• GOEDKOOP AY, DE RIE MA, PICAVET DI et al.: Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch. Dermatol. Res. (2004) 295:465-473.
   PubMed Web of Science ®Google Scholar
• DA SILVA AJ, BRICKELMAIER M, MAJEAU GR et al.: Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J. Immunol. (2002) 168:4462-4471.
   PubMed Web of Science ®Google Scholar
• LANGLEY R, ROENIGK HH, MCCALL C, STRICKLIN G, DINGIVAN C: Phase I results of intravenous MEDI-507, anti-T-cell monoclonal antibody, for the treatment of psoriasis. J. Invest. Dermatol. (2001) 117:817.
   Google Scholar
• ABRAMS JR, KELLEY SL, HAYES E et al.: Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J. Exp. Med. (2000) 192:681-694.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB AB, ABDULGHANI A, TOTORITIS M et al.: Results of a single-dose, dose-escalating trial of an anti-B7.1 monoclonal antibody (IDEC-114) in patients with psoriasis. J. Invest. Dermatol. (2000) 114:840.
   Google Scholar
• GOTTLIEB AB, KANG S, LINDEN KG et al.: Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin. Immunol. (2004) 111:28-37.
   PubMed Web of Science ®Google Scholar
• DE RIE MA, ZONNEVELD IM, WITKAMP L et al.: Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1. Acta Dermatol. Venereol. (1996) 76:357-360.
   PubMed Web of Science ®Google Scholar
• KRUEGER JG, WALTERS IB, MIYAZAWA M et al.: Successful in vivo blockade of CD25 (high-affinity interleulin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J. Am. Acad. Dermatol. (2000) 43:448-458.
   PubMed Web of Science ®Google Scholar
• OWEN CM, HARRISON PV: Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody. Clin. Exp. Dermatol. (2000) 25:195-197.
   PubMed Web of Science ®Google Scholar
• MROWIETZ U, ZHU K, CHRISTOPHERS E: Treatment of severe psoriasis with anti-CD25 monoclonal antibodies. Arch. Dermatol. (2000) 136:675-676.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB SL, GILLEAUDEAU P, JOHNSON R et al.: Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. (1995) 1:442-447.
   PubMed Web of Science ®Google Scholar
• BAGEL J, GARLAND WT, BRENEMAN D, HOLICK M, LITTLEJOHN TW: Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, Phase II multicenter trial. J. Am. Acad. Dermatol. (1998) 38:938-944.
   PubMed Web of Science ®Google Scholar
• MARTIN A, GUTIERREZ E, MUGLIA J et al.: A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis. J. Am. Acad. Dermatol. (2001) 45:871-881.
   PubMed Web of Science ®Google Scholar
• UYEMURA K, YAMAMURA M, FIVENSON DF et al.: The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J. Invest. Dermatol. (1993) 101:701-705.
   PubMed Web of Science ®Google Scholar
• ROSMARIN D, STROBER BE: The potential of interleukin-12 inhibition in the treatment of psoriasis. J. Drugs Dermatol. (2005) 4:318-325.
   PubMedGoogle Scholar
• ARICAN O, ARAL M, SASMAZ S, CIRAGIL P: Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. (2005) 24:273-279.
   Google Scholar
• PISKIN G, TURSEN U, SYLVA-STEENLAND RMR, BOS JD, TEUNISSEN MBM: Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-γ inducers – IL-12, IL-18 and IL-23. Exp. Dermatol. (2004) 13:764-772.
   PubMed Web of Science ®Google Scholar
• LEE E, TREPICCHIO WL, OESTREICHER JL et al.: Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. (2004) 199:125-130.
   PubMed Web of Science ®Google Scholar
• PISKIN G, SYLVA-STEENLAND RM, BOS JD, TEUNISSEN MB: In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J. Immunol. (2006) 176:1908-1915.
   PubMed Web of Science ®Google Scholar
• OPPMANN B, LESLEY R, BLOM B et al.: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity (2000) 13:715-725.
   PubMed Web of Science ®Google Scholar
• MUHL H, PFEILSCHIFTER J: Interleukin-18 bioactivity: a novel target for immunopharmacological anti-inflammatory intervention. Eur. J. Pharmacol. (2004) 500:63-71.
   PubMed Web of Science ®Google Scholar
• OHTA Y, HAMADA Y, KATSUOKA K: Expression of IL-18 in psoriasis. Arch. Dermatol. Res. (2001) 293:334-342.
   PubMed Web of Science ®Google Scholar
• COMPANJEN A, VAN DER WEL L, VAN DER FITS L, LAMAN J, PRENS E: Elevated interleukin-18 protein expression in early active and progressive plaque-type psoriatic lesions. Eur. Cytokine Netw. (2004) 15:210-216.
   PubMed Web of Science ®Google Scholar
• WITTMANN M, PURWAR R, HARTMANN C, GUTZMER R, WERFEL T: Human keratinocytes respond to interleukin-18: implication for the course of chronic inflammatory skin diseases. J. Invest. Dermatol. (2005) 124:1225-1233.
   PubMed Web of Science ®Google Scholar
• GUTZMER R, LANGER K, MOMMERT S, WITTMANN M, KAPP A, WERFEL T: Human dendritic cells express the IL-18R and are chemoattracted to IL-18. J. Immunol. (2003) 171:6363-6371.
   PubMed Web of Science ®Google Scholar
• KASHIWAMURA S, UEDA H, OKAMURA H: Roles of interleukin-18 in tissue destruction and compensatory reactions. J. Immunother. (2002) 25(Suppl. 1):S4-S11.
   PubMed Web of Science ®Google Scholar
• RUCKERT R, ASADULLAH K, SEIFERT M et al.: Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis? J. Immunol. (2000) 165:2240-2250.
   PubMed Web of Science ®Google Scholar
• MCINNES IB, GRACIE JA: Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr. Opin. Pharmacol. (2004) 4:392-397.
   PubMed Web of Science ®Google Scholar
• TEUNISSEN MB, KOOMEN CW, DE WAAL MALEFYT R, WIERENGA EA, BOS JD: Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J. Invest. Dermatol. (1998) 111:645-649.
   PubMed Web of Science ®Google Scholar
• AGGARWAL S, GHILARDI N, XIE MH, DE SAUVAGE FJ, GURNEY AL: Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. (2003) 278:1910-1914.
   PubMed Web of Science ®Google Scholar
• WANG F, LEE E, LOWES MA et al.: Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: gene regulation and cellular effects. J. Invest. Dermatol. (2006) 126:1590-1599.
   PubMed Web of Science ®Google Scholar
• WOLK K, WITTE E, WALLACE E et al.: IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur. J. Immunol. (2006) 36:1309-1323.
   PubMed Web of Science ®Google Scholar
• RINCÓN M, PEDRAZA-ALVA G: JNK and p38 MAP kinases in CD4+ and CD8+ T cells. Immunol Rev (2003) 192:131-142.
   PubMed Web of Science ®Google Scholar
• ZHANG J, SALOJIN KV, GAO JX, CAMERON MJ, BERGEROT I, DELOVITCH TL: p38 mitogen-activated protein kinase mediates signal integration of TCR/CD28 costimulation in primary murine T cells. J. Immunol. (1999) 162:3819-3829.
   PubMed Web of Science ®Google Scholar
• ELLERY JM, NICHOLLS PJ: Alternate signalling pathways from the interleukin-2 receptor. Cytokine Growth Factor Rev. (2002) 13:27-40.
   PubMed Web of Science ®Google Scholar
• JOHANSEN C, KRAGBALLE K, WESTERGAARD M, HENNINGSEN J, KRISTIANSEN K, IVERSEN L: The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br. J. Dermatol. (2005) 152:37-42.
   PubMed Web of Science ®Google Scholar
• WAGNER G, LAUFER S: Small molecular anti-cytokine agents. Med. Res. Rev. (2006) 26:1-62.
   PubMed Web of Science ®Google Scholar
• KAWAGUCHI M, MITSUHASHI Y, KONDO S: Overexpression of tumour necrosis factor-alpha-converting enzyme in psoriasis. Br. J. Dermatol. (2005) 152:915-919.
   PubMed Web of Science ®Google Scholar
• ASADULLAH K, SABAT R, FRIEDRICH M, VOLK HD, STERRY W: Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis. Curr. Drug Targets Inflamm. Allergy (2004) 3:185-192.
   PubMedGoogle Scholar
• MARTIN R: Interleukin 4 treatment of psoriasis: are pleiotropic cytokines suitable therapies for autoimmune diseases? Trends Pharmacol. Sci. (2003) 24:613-616.
   PubMed Web of Science ®Google Scholar
• DOI H, SHIBATA MA, KIYOKANE K, OTSUKI Y: Downregulation of TGFbeta isoforms and their receptors contributes to keratinocyte hyperproliferation in psoriasis vulgaris. J. Dermatol. Sci. (2003) 33:7-16.
   PubMed Web of Science ®Google Scholar
• KIMBALL B, KAWAMURA T, TEJURA K et al.: Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin-10. Arch. Dermatol. (2002) 138:1341-1346.
   PubMed Web of Science ®Google Scholar
• RAYCHAUDHURI SP, FARBER EM, RAYCHAUDHURI SK: Immunomodulatory effects of peptide T on Th 1/Th 2 cytokines. Int. J. Immunopharmacol. (1999) 21:609-615.
   PubMed Web of Science ®Google Scholar
• MCCOLL SR, ST-ONGE M, DUSSAULT AA et al.: Immunomodulatory impact of the A2A adenosine receptor on the profile of chemokines produced by neutrophils. FASEB J. (2006) 20:187-189.
   PubMedGoogle Scholar
• LAPPAS CM, SULLIVAN GW, LINDEN J: Adenosine A2A agonists in development for the treatment of inflammation. Expert Opin. Investig. Drugs. (2005) 14:797-798.
   PubMed Web of Science ®Google Scholar
• ERDMANN AA, GAO ZG, JUNG U et al.: Activation of TH1 and TC1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood (2005) 105:4707-4714.
   PubMed Web of Science ®Google Scholar
• HILL RP, MACNEIL S, HAYCOCK JW: Melanocyte stimulating hormone peptides inhibit TNF-alpha signaling in human dermal fibroblast cells. Peptides (2006) 27:421-430.
   PubMed Web of Science ®Google Scholar
• IRONY-TUR-SINAI M, GRIGORIADIS N, LOURBOPOULOS A, PINTO-MAARAVI F, ABRAMSKY O, BRENNER T: Amelioration of autoimmune neuroinflammation by recombinant human alpha-fetoprotein. Exp. Neurol. (2006) 198:136-144.
   PubMed Web of Science ®Google Scholar
• LEWIS EC, SHAPIRO L, BOWERS OJ, DINARELLO CA: Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice. Proc. Natl. Acad. Sci. USA (2005) 102:12651-12652.
   PubMed Web of Science ®Google Scholar
• FUHLBRIGGE RC, KING SL, SACKSTEIN R, KUPPER TS: CD43 is a ligand for E-selectin on CLA+ human T cells. Blood (2006) 107:1421-1426.
   PubMed Web of Science ®Google Scholar
• BHUSHAN M, BLEIKER TO, BALLSDON AE et al.: Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br. J. Dermatol. (2002) 146:824-831.
   PubMed Web of Science ®Google Scholar
• FRIEDRICH M, BOCK D, PHILIPP S et al.: Pan-selectin antagonism improves psoriasis manifestation in mice and man. Arch. Dermatol. Res. (2006) 297:345-351.
   PubMed Web of Science ®Google Scholar
• PASTORE S, MASCIA F, MARIOTTI F, DATTILO C, GIROLOMONI G: Chemokine networks in inflammatory skin diseases. Eur. J. Dermatol. (2004) 14:203-208.
   PubMed Web of Science ®Google Scholar
• RAYCHAUDHURI SP, JIANG WY, FARBER EM, SCHALL TJ, RUFF MR, PERT CB: Upregulation of RANTES in psoriatic keratinocytes: a possible pathogenic mechanism for psoriasis. Acta Derm. Venereol. (1999) 79:9-11.
   PubMed Web of Science ®Google Scholar
• ROTTMAN JB, SMITH TL, GANLEY KG, KIKUCHI T, KRUEGER JG: Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab. Invest. (2001) 81:335-347.
   PubMed Web of Science ®Google Scholar
• MAGLIOCCO MA: Emerging drugs for moderate-to-severe psoriasis. Expert Opin. Emerg. Drugs (2005) 10:35-52.
   PubMedGoogle Scholar
• VUGMEYSTER Y, KIKUCHI T, LOWES MA et al.: Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin. Immunol. (2004) 113:38-46.
   PubMed Web of Science ®Google Scholar
• HIGASHIYAMA M, MATSUMOTO K, HASHIMOTO K, YOSHIKAWA K: Increased production of transforming growth factor-alpha in psoriatic epidermis. J. Dermatol. (1991) 18:117-119.
   PubMedGoogle Scholar
• EDMONDSON SR, THUMIGER SP, WERTHER GA, WRAIGHT CJ: Epidermal homeostasis: the role of the growth hormone and insulin-like growth factor systems. Endocr. Rev. (2003) 24:737-764.
   PubMed Web of Science ®Google Scholar
• FINCH PW, MURPHY F, CARDINALE I, KRUEGER JG: Altered expression of keratinocyte growth factor and its receptor in psoriasis. Am. J. Pathol. (1997) 151:1619-1628.
   PubMed Web of Science ®Google Scholar
• KOVACS D, FALCHI M, CARDINALI G et al.: Immunohistochemical analysis of keratinocyte growth factor and fibroblast growth factor 10 expression in psoriasis. Exp. Dermatol. (2005) 14:130-137.
   PubMed Web of Science ®Google Scholar
• PIEPKORN M: Overexpression of amphiregulin, a major autocrine growth factor for cultured human keratinocytes, in hyperproliferative skin diseases. Am. J. Dermatopathol. (1996) 18:165-171.
   PubMed Web of Science ®Google Scholar
• CHUNG E, COOK PW, PARKOS CA, PARK YK, PITTELKOW MR, COFFEY RJ: Amphiregulin causes functional downregulation of adherens junctions in psoriasis. J. Invest. Dermatol. (2005) 124:1134-1140.
   PubMed Web of Science ®Google Scholar
• JOST M, CLASS R, KARI C et al.: A central role of Bcl-X(L) in the regulation of keratinocyte survival by autocrine EGFR ligands. J. Invest. Dermatol. (1999) 112:443-449.
   PubMed Web of Science ®Google Scholar
• VARANI J, LATEEF H, FAY K, ELDER JT: Antagonism of epidermal growth factor receptor tyrosine kinase ameliorates the psoriatic phenotype in organ-cultured skin. Skin Pharmacol. Physiol. (2005) 18:123-131.
   PubMed Web of Science ®Google Scholar
• WHITE PJ, ATLEY LM, WRAIGHT CJ: Antisense oligonucleotide treatments for psoriasis. Expert Opin. Biol. Ther. (2004) 4:75-81.
   PubMed Web of Science ®Google Scholar
• QIN JZ, CHATURVEDI V, DENNING MF, CHOUBEY D, DIAZ MO, NICKOLOFF BJ: Role of NF-kappaB in the apoptotic-resistant phenotype of keratinocytes. J. Biol. Chem. (1999) 274:37957-37964.
   PubMed Web of Science ®Google Scholar
• AHMAD N, MUKHTAR H: Cytochrome P450: a target for drug development for skin diseases. J. Invest. Dermatol. (2004) 123:417-425.
   PubMed Web of Science ®Google Scholar
• MCKENZIE RC, SABIN E: Aberrant signalling and transcription factor activation as an explanation for the defective growth control and differentiation of keratinocytes in psoriasis: a hypothesis. Exp. Dermatol. (2003) 12:337-345.
   PubMed Web of Science ®Google Scholar
• HOLICK MF, CHIMEH FN, RAY S: Topical PTH (1–34) is a novel, safe and effective treatment for psoriasis: a randomized self-controlled trial and an open trial. Br. J. Dermatol. (2003) 149:370-376.
   PubMed Web of Science ®Google Scholar
• CREAMER D, SULLIVAN D, BICKNELL R, BARKER J: Angiogenesis in psoriasis. Angiogenesis (2002) 5:231-236.
   PubMedGoogle Scholar
• BHUSHAN M, MCLAUGHLIN B, WEISS JB, GRIFFITHS CE: Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br. J. Dermatol. (1999) 141:1054-1060.
   PubMed Web of Science ®Google Scholar
• IKAI K: Psoriasis and the arachidonic acid cascade. J. Dermatol. Sci. (1999) 21:135-146.
   PubMed Web of Science ®Google Scholar
• RAYCHAUDHURI SP, RAYCHAUDHURI SK: Role of NGF and neurogenic inflammation in the pathogenesis of psoriasis. Prog. Brain Res. (2004) 146:433-437.
   PubMed Web of Science ®Google Scholar
• OZAWA M, TERUI T, TAGAMI H: Localization of IL-8 and complement components in lesional skin of psoriasis vulgaris and pustulosis palmaris et plantaris. Dermatology (2005) 211:249-255.
   PubMed Web of Science ®Google Scholar
• HOUSLAY MD, SCHAFER P, ZHANG KY: Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov. Today (2005) 10:1503-1519.
   PubMed Web of Science ®Google Scholar
• ORTONNE JP, VAN DE KERKHOF PC, PRINZ JC et al.: EUROPEAN TACROLIMUS PSORIASIS STUDY GROUP: 0.3% tacrolimus gel and 0.5% tacrolimus cream show efficacy in mild to moderate plaque psoriasis: results of a randomized, open-label, observer-blinded study. Acta Derm. Venereol. (2006) 86:29-33.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB AB, GRIFFITHS CE, HO VC et al.: Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. Br. J. Dermatol. (2005) 152:1219-1227.
   PubMed Web of Science ®Google Scholar
• MROWIETZ U, WUSTLICH S, HOEXTER G, GRAEBER M, BRAUTIGAM M, LUGER T: An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm. Venereol. (2003) 83:351-353.
   PubMed Web of Science ®Google Scholar
• BISSONNETTE R, PAPP K, POULIN Y et al.: ISA-247 PSORIASIS STUDY GROUP: A randomized, multicenter, double-blind, placebo-controlled Phase II trial of ISA247 in patients with chronic plaque psoriasis. J. Am. Acad. Dermatol. (2006) 54:472-478.
   PubMed Web of Science ®Google Scholar
• PAPP K, LANGLEY R, BISSONNETTE R, ROSOPH L: A Phase III, randomized, multicenter, double-blind, placebo-controlled study of ISA247 in plaque psoriasis patients. J. Am. Acad. Dermatol. (2006) 54(3):Abstract P33.
   Google Scholar
• GOTTLIEB AB, ROHANE P, JONES M: Biological activity of CC-10004 in patients with severe plaque-type psoriasis. J. Am. Acad. Dermatol. (2006) 54(3):Abstract P34.
   Google Scholar
• GOTTLIEB A, CATHER J, HAMILTON T, SHERMAN M: Preliminary clinical safety and efficacy results from an open-label Phase II study of STA-5326, an oral IL-12/IL-23 inhibitor, in patients with moderate to severe chronic plaque psoriasis. J. Am. Acad. Dermatol. (2006) 54(3):Abstract P37.
   Google Scholar
• KRUEGER GG, LANGLEY R, LEONARDI C, LEBWOHL M: Results of a Phase II study of CNTO 1275 in the treatment of psoriasis. J. Am. Acad. Dermatol. (2006) 54(3):Abstract P38.
   PubMedGoogle Scholar
• LANGLEY R, LEONARDI C, TOTH D, CHEN D: Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis. J. Am. Acad. Dermatol. (2005) 52(3):Abstract P8.
   PubMedGoogle Scholar
• BERTH-JONES J, TODD G, HUTCHINSON PE, THESTRUP-PEDERSEN K, VANHOUTTE FP: Treatment of psoriasis with oral liarozole: a dose-ranging study. Br. J. Dermatol. (2000) 143:1170-1176.
   PubMed Web of Science ®Google Scholar
• BHUSHAN M, BURDEN AD, MCELHONE K, JAMES R, VANHOUTTE FP, GRIFFITHS CE: Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. Br. J. Dermatol. (2001) 145:546-553.
   PubMed Web of Science ®Google Scholar
• SMIT JV, FRANSSEN ME, DE JONG EM et al.: A Phase II multicenter clinical trial of systemic bexarotene in psoriasis. J. Am. Acad. Dermatol. (2004) 51:249-256.
   PubMed Web of Science ®Google Scholar
• MOORE AY: Oral bexarotene and narrowband UVB phototherapy in the treatment of moderate-to-severe plaque psoriasis. Poster 613 presented at: The 61st Annual Meeting of the American Academy of Dermatology. San Francisco, CA, USA March 21-26 (2003).
   Google Scholar
• MAGLIOCCO MA, PANDYA K, DOMBROVSKIY V, CHRISTIANSEN L, WONG Y, GOTTLIEB AB: A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB phototherapy for moderate to severe psoriasis vulgaris. J. Am. Acad. Dermatol. (2006) 54:115-118.
   PubMed Web of Science ®Google Scholar
• SAUDER DN, DEKOVEN J, CHAMPAGNE P, CROTEAU D, DUPONT E: Neovastat (AE-941), an inhibitor of angiogenesis: randomized Phase I/II clinical trial results in patients with plaque psoriasis. J. Am. Acad. Dermatol. (2002) 47:535-541.
   PubMed Web of Science ®Google Scholar
• EHRLICH A, BOOHER S, BECERRA Y et al.: Micellar paclitaxel improves severe psoriasis in a prospective Phase II pilot study. J. Am. Acad. Dermatol. (2004) 50:533-540.
   PubMed Web of Science ®Google Scholar